John W Smith - JoVE Visualize

Showing results (31-40 of 41) with videos related to

Pageof 5

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cellsEdwin B Walker, Daniel Haley, William Miller, et al.

Human Gene Therapy|July 30, 2003

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological resultsAnnemieke Dols, John W Smith, Sybren L Meijer, et al.

Ecological Applications : a Publication of the Ecological Society of America|November 20, 2021

Increased adoption of best practices in ecological forecasting enables comparisons of forecastabilityAbigail S L Lewis, Whitney M Woelmer, Heather L Wander, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2013

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancerFabrice André, Thomas Bachelot, Mario Campone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003

Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responsesJohn W Smith, Edwin B Walker, Bernard A Fox, et al.

Clinical Breast Cancer|May 17, 2011

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trialNicholas J Robert, Mansoor N Saleh, Devchand Paul, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.

Clinical Breast Cancer|October 4, 2016

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5John W Smith, Marc E Buyse, Priya Rastogi, et al.

NPJ Breast Cancer|June 12, 2021

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patientsCostanza Paoletti, Meredith M Regan, Samuel M Niman, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.

Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:

Pageof 5

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004

gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cellsEdwin B Walker, Daniel Haley, William Miller, et al.

Human Gene Therapy|July 30, 2003

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological resultsAnnemieke Dols, John W Smith, Sybren L Meijer, et al.

Ecological Applications : a Publication of the Ecological Society of America|November 20, 2021

Increased adoption of best practices in ecological forecasting enables comparisons of forecastabilityAbigail S L Lewis, Whitney M Woelmer, Heather L Wander, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2013

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancerFabrice André, Thomas Bachelot, Mario Campone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003

Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responsesJohn W Smith, Edwin B Walker, Bernard A Fox, et al.

Clinical Breast Cancer|May 17, 2011

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trialNicholas J Robert, Mansoor N Saleh, Devchand Paul, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.

Clinical Breast Cancer|October 4, 2016

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5John W Smith, Marc E Buyse, Priya Rastogi, et al.

NPJ Breast Cancer|June 12, 2021

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patientsCostanza Paoletti, Meredith M Regan, Samuel M Niman, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.

Pageof 5